This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kriström, B. Articles by Albertsson-Wikland, K. Search for Related Content PubMed PubMed Citation Articles by Kriström, B. Articles by Albertsson-Wikland, K.

Growth Response to Growth Hormone (GH) Treatment Relates to Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Short Children with Various GH Secretion Capacities¹

Department of Pediatrics, University of Umea (B.K.), Umea; and University of Goteborg (B.K., C.J., S.R., K.A.-W.), Goteborg, Sweden

Address all correspondence and requests for reprints to: Dr. Berit Kriström, University of Goteborg, Department of Pediatrics, International Pediatric Growth Research Center, Sahlgrenska University Hospital East, S-416 85 Goteburg, Sweden. E-mail: Berit.Kristrom{at}pediatri.umu.se

The purpose of the study was to evaluate the relationship between the 1-yr (n = 193) and 2-yr (n = 128) growth response and the individual serum concentrations of insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) before and during GH treatment. Our study group of prepubertal short children had from very low to high GH secretory capacity, estimated during an arginine-insulin tolerance test, and the ages ranged from 3–15 yr at the start of treatment. Their serum levels of IGF-I and IGFBP-3 were low before treatment compared to those in an age-related reference group of prepubertal children and increased significantly from the start to 1 month of GH treatment. The mean increase in height SD score was 0.80 SD score after 1 yr of GH treatment and 1.26 SD score after 2 yr, with a wide range. In univariate analyses the highest correlation coefficients to the 2-yr growth response were found to be vs. the following variables from the start of treatment: IGF-I SD score (r = -0.49), log maximum GH concentration (log GH_max) during the arginine-insulin tolerance test (r = -0.47), difference between the height SD score of the individual child and the midparental height SD score (diffSD score; r = -0.45), IGFBP-3 SD score (r = -0.39), age (r = -0.30), short term change in IGFBP-3 SD score (r = 0.37), and IGF-I SD score (r = 0.34). In multivariate stepwise regression analysis, 41% of the variation in the 2-yr growth response could be explained by IGF-I SD score or log GH_max together with age at the start of treatment, weight SD score at 1 yr of age, and diffSD score. When both IGF-I SD score and GH_max were included and when the short term changes in IGF-I SD score were added, 46% and 58% of the variation, respectively, could be explained. The regression algorithms using different combinations of variables and their corresponding prediction intervals are also presented.

This article has been cited by other articles:

				B. Kristrom, A. S. Aronson, J. Dahlgren, J. Gustafsson, M. Halldin, S. A. Ivarsson, N.-O. Nilsson, J. Svensson, T. Tuvemo, and K. Albertsson-Wikland Growth Hormone (GH) Dosing during Catch-Up Growth Guided by Individual Responsiveness Decreases Growth Response Variability in Prepubertal Children with GH Deficiency or Idiopathic Short Stature J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 483 - 490. [Abstract] [Full Text] [PDF]

				J. Baron Growth Hormone Therapy in Childhood: Titration Versus Weight-Based Dosing? J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2436 - 2438. [Full Text] [PDF]

				N. Bouhours-Nouet, F. Gatelais, F. Boux de Casson, S. Rouleau, and R. Coutant The Insulin-Like Growth Factor-I Response to Growth Hormone Is Increased in Prepubertal Children with Obesity and Tall Stature J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 629 - 635. [Abstract] [Full Text] [PDF]

				C Land, W F Blum, A Stabrey, and E Schoenau Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency Eur. J. Endocrinol., May 1, 2005; 152(5): 727 - 733. [Abstract] [Full Text] [PDF]

				C. Lofqvist, E. Andersson, L. Gelander, S. Rosberg, L. Hulthen, W. F. Blum, and K. A. Wikland Reference Values for Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) and the Ratio of Insulin-Like Growth Factor-I to IGFBP-3 throughout Childhood and Adolescence J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1420 - 1427. [Abstract] [Full Text] [PDF]

				R. Coutant, F. B. de Casson, S. Rouleau, O. Douay, E. Mathieu, F. Gatelais, N. Bouhours-Nouet, C. Voinot, M. Audran, and J. M. Limal Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6185 - 6192. [Abstract] [Full Text] [PDF]

				R. Bjarnason, B. Andersson, H. S. Kim, B. Olsson, D. Swolin-Eide, R. Wickelgren, B. Kristrom, B. Carlsson, K. Albertsson-Wikland, L. M. S. Carlsson, et al. Cartilage Oligomeric Matrix Protein Increases in Serum after the Start of Growth Hormone Treatment in Prepubertal Children J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5156 - 5160. [Abstract] [Full Text] [PDF]

				J. M. Wit and L. T. M. Rekers-Mombarg Final Height Gain by GH Therapy in Children with Idiopathic Short Stature Is Dose Dependent J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 604 - 611. [Abstract] [Full Text] [PDF]

				R. Coutant, F. Boux de Casson, S. Rouleau, O. Douay, E. Mathieu, M. Audran, and J. M. Limal Body Composition, Fasting Leptin, and Sex Steroid Administration Determine GH Sensitivity in Peripubertal Short Children J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5805 - 5812. [Abstract] [Full Text] [PDF]

				C. Lofqvist, E. Andersson, L. Gelander, S. Rosberg, W. F. Blum, and K. A. Wikland Reference Values for IGF-I throughout Childhood and Adolescence: A Model that Accounts Simultaneously for the Effect of Gender, Age, and Puberty J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5870 - 5876. [Abstract] [Full Text] [PDF]

				M. B. Ranke, A. Lindberg, P. Chatelain, P. Wilton, W. Cutfield, K. Albertsson-Wikland, and D. A. Price Derivation and Validation of a Mathematical Model for Predicting the Response to Exogenous Recombinant Human Growth Hormone (GH) in Prepubertal Children with Idiopathic GH Deficiency J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1174 - 1183. [Abstract] [Full Text]

				H. Olivecrona, A. Hilding, C. Ekström, H. Barle, B. Nyberg, C. Möller, P. J. Delhanty, R. C. Baxter, B. Angelin, T. J. Ekström, et al. Acute and Short-Term Effects of Growth Hormone on Insulin-Like Growth Factors and Their Binding Proteins: Serum Levels and Hepatic Messenger Ribonucleic Acid Responses in Humans J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 553 - 560. [Abstract] [Full Text]

				B. Kriström, B. Carlsson, S. Rosberg, L. M. S. Carlsson, and K. Albertsson-Wikland Short-Term Changes in Serum Leptin Levels Provide a Strong Metabolic Marker for the Growth Response to Growth Hormone Treatment in Children J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2735 - 2741. [Abstract] [Full Text]